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Microbial 1,2-dihydroxylation of sodium benzoate permits 
rapid construction of novel inositol-amino acid hybrid 
structures. Both β- and γ-amino acids are accessible by means 
of an acylnitroso Diels–Alder cycloaddition.  
 10 
Azacarbasugars are a privileged class of structures for drug 
development as the amino functionality can modulate biological 
activity with respect to the parent carbohydrate and replacement 
of the endocyclic oxygen with carbon confers hydrolytic 
stability.1 Azacarbasugar motifs are present in many compounds 15 
of medicinal interest. Acarbose 1 and voglibose 2 are α-
glucosidase inhibitors used clinically to treat type II diabetes.2,3 
Antibiotic4 and antifungal4b,5 properties of azacarbasugars have 
been reported. The use of N-octylvalienamine 3 and its 4-epimer 
as therapies for Gaucher disease and GM1-gangliosidosis is under 20 
investigation.6 In addition, the anti-influenza drug oseltamivir 4 
may also be considered to be an azacarbasugar (Figure 1).7  
 
Fig. 1 Representative azacarbasugars and cyclic amino acids. 
In the field of peptide engineering, incorporation of non-natural 25 
β- and γ- amino acids has been employed to furnish peptides with 
designed properties.8 Constrained cyclic amino acids are effective 
for imparting secondary structure to peptides and the cyclohexane 
γ-amino acid 5 has been employed for the construction of peptide 
nanotubes with hydrophobic cavities.9 Polyhydroxylated 30 
analogues of 5 would permit control of the hydrophobicity of 
such cavities and allow for modified secondary structures based 
on additional hydrogen bonding interactions. 
 Enzymatic dihydroxylation of arenes to produce enantiopure 
building blocks for synthesis is well established methodology.10 35 
For dihydroxylation of monosubstituted arenes, the most common 
regiochemical outcome is installation of the diol ortho,meta to the 
pre-existing substituent (7, Scheme 1a). However, R. eutrophus 
B911,† and certain other organisms12 are able to metabolise 
benzoates such that the diol is introduced ipso,ortho to the 40 
carboxy functionality (Scheme 1b). The chiron 9 derived from the 
oxidation of benzoate has found diverse synthetic applications13 
and we have recently demonstrated access to new reaction 
manifolds by means of tricarbonyliron complexes of 9.14  Arene 
diols are ideal starting materials for azacarbasugar synthesis; 45 
ortho,meta diols of type 7 have been utilised in this context.15 In 
contrast, ipso,ortho diols of type 9 have remained unexploited to 
date. We targeted efficient access to C-substituted azacarbasugar 
structures from 9, made possible by the pre-existing quaternary 
centre. Specifically, we sought to access C-carboxy inosamines 50 
(“InosAminoAcids”), a hitherto unknown class of compound. 
 
Scheme 1 Regio- and stereoselectivity of dioxygenases. 
Formation of the known13a,g acetonide of 9, followed by 
carboxylate benzylation afforded protected diene 10, which was 55 
employed in an acylnitroso cycloaddition. The dienophile was 
generated in situ by the action of tetrabutylammonium periodate 
on N-(benzyloxycarbonyl)hydroxylamine 11.15h,16 Selectivity in 
cycloadditions employing arene diol-derived dienes has been 
extensively studied17 and precedent suggested that approach of 60 
the dienophile to the diene face opposite the acetonide would be 
favoured.13a,15h,16b,c,18 In the event, only two of four possible 
regioisomers were isolated (12 and 13, Scheme 2). 
 
Scheme 2 Acylnitroso cycloaddition. 65 
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The major product of the cycloaddition (12) was that in which the 
Cbz group was introduced distal to the benzyl ester, which we 
attribute to decreased steric hindrance with respect to formation 
of 13. Major adduct 12 was treated with molybdenum 
hexacarbonyl to effect selective N–O bond scission, followed by 5 
formation of crystalline p-nitrobenzoate derivative 15. The 
absolute structure of 15 was confirmed by X-ray crystallography, 
from which the structure of 12 was inferred. The same sequence 
of transformations did not furnish a crystalline derivative when 
applied to minor adduct 13. Thus, the structure of 13 was 10 
elucidated by means of NOESY correlations.‡ Specifically, an 
interaction between the olefinic protons and the acetonide endo 
methyl protons was observed for both 12 and 13; such an 
interaction would not be expected for cycloadducts arising from 
dienophile approach to the diene face bearing the acetonide. 15 
 
Scheme 3 Structural elucidation of 12 and 13. NOESY correlations are 
shown with double-headed arrows. ORTEP Diagram of 15 shows 
ellipsoids at 50% probability. Solvent and disorder in the Cbz phenyl ring 
are omitted for clarity. H atoms are shown as spheres of arbitrary radius. 20 
 
Scheme 4 (a) NMO, cat. OsO4, acetone/H2O 4:1, 24 h, rt. NOESY 
correlations are shown with double-headed arrows. 
Cycloadducts 12 and 13 were subjected to Upjohn 
dihydroxylation conditions, affording in each instance the diol 25 
corresponding to approach of the oxidant to the less hindered face 
of the olefin. Stereochemistry of addition was again elucidated by 
NOESY correlation‡ (Scheme 4). For both diols 16 and 18, 
interaction of the acetonide endo methyl protons with the 
hydroxyl group methines was observed, indicative of the axial 30 
orientation of the methines and, by inference, the equatorial 
orientation of the hydroxyl groups. In the dihydroxylation of 12, 
unexpected cyclic carbamate 17 was also formed. Hydrogenolysis 
of diols 16 and 18 effected multiple reductive operations cleanly, 
allowing access to the target inosaminoacids 20 and 22 (Scheme 35 
5) simply by acetonide removal in aqueous hydrochloric acid.19 
Scheme 5 (a) H2, Pd/C, MeOH, 24 h, rt.  (b) 1 M HCl(aq), 24 h, rt.  (c) C18 
reversed-phase chromatography.  (d) Trituration with EtOH 
 40 
In adddition to inosaminoacids 20 and 22, less highly oxygenated 
structures are also accessible via the acylnitroso cycloaddition 
reported here. For example, major cycloadduct 12 could be 
subjected directly to hydrogenolysis/acetonide cleavage as above, 
in this instance giving rise to dihydro-3-C-carboxy-ent-45 
conduramine A1 (24, Scheme 6).20 Polyhydroxylated zwitterionic 
species such as 19-24 are known to be difficult to purify; repeated 
chromatography was required in some instances.19 
 
Scheme 6 (a) H2, Pd/C, MeOH, 24 h, rt.  (b) 1 M HCl(aq), 24 h, rt.  (c) C18 50 
reversed-phase chromatography. 
Conduramine derivative 24 was highly crystalline and submitted 
to X-ray crystallography (Figure 2), providing further 
confirmation for the assignment of 12 and 13. It is noteworthy 
that in the solid state 24 adopts a near-perfect chair conformation. 55 
 
Fig. 2 ORTEP Diagram of 24 shows ellipsoids at 50% probability. H 
atoms are shown as spheres of arbitrary radius. 
Inosaminoacids 20 and 22 and conduramine derivative 24 were 
evaluated for inhibition of glycosidase activity21 against -60 
glucosidase (type I from Baker’s yeast), -D-glucosidase 
(almond), -galactosidases (from A. oryzae and E. coli) and -D-
glucuronidases (from bovine liver, E. coli and P. vulgata); no 
inhibitory activity was observed. 
 In summary, we have described a very concise synthetic route 65 
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to a novel class of azacarbasugar. Inosaminoacids 20 and 22 
contain six contiguous stereocentres (including a quaternary 
centre), yet are accessed in just seven steps from sodium 
benzoate. Current work in our laboratory concerns accessing 
inosaminoacids having alternative stereochemistries and their 5 
incorporation into oligopeptides. 
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